Key Points
- COO Joseph Gilliam sold 10,498 shares on Jan. 22 at an average price of $127.68 for about $1.34M, cutting his stake by 10.21% to 92,366 shares (≈$11.8M).
- Glaukos stock opened at $124.29 and was trading up 3.6%; the company has a $7.14B market cap, a negative P/E, a 52-week range of $73.16–$161.78, and last quarter beat EPS estimates while reporting 38.1% revenue growth year-over-year.
- Analysts maintain a "Moderate Buy" consensus with an average target of $131.38, with several firms raising targets (e.g., Stifel to $160, Piper Sandler $165) alongside a few sell ratings.
Glaukos Corporation (NYSE:GKOS - Get Free Report) COO Joseph Gilliam sold 10,498 shares of the firm's stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $127.68, for a total transaction of $1,340,384.64. Following the sale, the chief operating officer owned 92,366 shares of the company's stock, valued at approximately $11,793,290.88. This represents a 10.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Glaukos Trading Up 3.6%
NYSE:GKOS opened at $124.29 on Tuesday. The company's 50 day moving average price is $111.25 and its 200-day moving average price is $96.29. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $161.78. The company has a quick ratio of 4.47, a current ratio of 5.20 and a debt-to-equity ratio of 0.09. The stock has a market cap of $7.14 billion, a price-to-earnings ratio of -80.71 and a beta of 0.67.
Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.11. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.52%. The company had revenue of $133.54 million during the quarter, compared to analyst estimates of $122.55 million. During the same period in the previous year, the business earned ($0.28) EPS. The firm's revenue for the quarter was up 38.1% on a year-over-year basis. On average, equities research analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several research firms recently commented on GKOS. Needham & Company LLC reiterated a "buy" rating and issued a $125.00 price objective on shares of Glaukos in a report on Wednesday, January 14th. Citigroup lifted their price target on shares of Glaukos from $113.00 to $125.00 and gave the stock a "buy" rating in a research note on Thursday, December 11th. Weiss Ratings reissued a "sell (d-)" rating on shares of Glaukos in a report on Thursday. Stifel Nicolaus raised their target price on shares of Glaukos from $115.00 to $160.00 and gave the stock a "buy" rating in a report on Thursday, January 22nd. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $165.00 target price on shares of Glaukos in a research report on Wednesday, January 14th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, Glaukos has a consensus rating of "Moderate Buy" and an average target price of $131.38.
Check Out Our Latest Report on GKOS
Institutional Trading of Glaukos
Several large investors have recently added to or reduced their stakes in GKOS. UMB Bank n.a. increased its holdings in Glaukos by 102.6% during the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier's stock valued at $25,000 after buying an additional 158 shares during the last quarter. Park Place Capital Corp grew its position in shares of Glaukos by 68.4% during the 2nd quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier's stock valued at $41,000 after acquiring an additional 162 shares during the period. Farther Finance Advisors LLC increased its stake in shares of Glaukos by 111.4% in the 4th quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier's stock worth $46,000 after purchasing an additional 215 shares in the last quarter. REAP Financial Group LLC bought a new position in Glaukos in the 3rd quarter worth $40,000. Finally, AlphaQuest LLC lifted its position in Glaukos by 5,754.5% during the second quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier's stock valued at $67,000 after purchasing an additional 633 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors.
About Glaukos
(
Get Free Report)
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
